Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC Injection for Moderate to Severe ARDS
NCT07413978Phase 2Recruiting
- Sponsor
- Changchun Tuohua Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of human umbilical cord mesenchymal stem cells in acute respiratory distress syndrome (ARDS), sponsored by Changchun Tuohua Pharmaceutical. Primary endpoints: Dose Limiting Toxicity incidence rate at 28 days, Maximum Tolerated Dose and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07413978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413978.